Abstract P2-12-08: Oncologic outcomes after nipple-sparing mastectomy: A single-institution experience

Abstract

Abstract Introduction: Nipple-sparing mastectomy (NSM) is the latest advancement in the treatment of breast cancer. Long-term oncologic outcomes in nipple-sparing mastectomy (NSM) continue to be defined. Rates of locoregional recurrence for skin-sparing mastectomy (SSM) and NSM in the literature range from 0 to 14.3%. We investigated the outcomes of NSM at our institution. Methods: Patients undergoing NSM at our institution from 2006 to 2014 were identified. Patient demographics, tumor characteristics, and outcomes were collected. Locoregional recurrence was compared to previously published NSM and SSM results compiled from 14 and 11 studies in the literature. Institutional review board approval was obtained prior to the initiation of this study. Results: From 2006 to 2014, 319 patients (555 breasts) underwent NSM. 149 patients (248 breasts) had long-term follow-up available. Average patient age and BMI were 47.4 and 24.28. Eighty-five percent of patients underwent mastectomy primarily for a therapeutic indication. Average tumor size was 1.41 centimeters with the most common histologic type being invasive ductal carcinoma (66.7%) followed by DCIS (23.8%). Nodal disease was present in 14.8% of patients. Average patient follow-up was 30.72 months. There was one (0.7%) incidence of ipsilateral chest-wall recurrence in a 44 year-old (p<0.0001, compared to aggregate NSM and SSM data). There were 0.36 complications per patient. There were 3 incidences of nipple-areola complex (NAC) necrosis: 2 partial thickness necrosis and 1 full thickness necrosis. Patient Demographics and Tumor CharacteristicsAge (years)47.7RaceCaucasian: 127 (85.2%) Non-Caucasian: 22 (14.8%)BMI24.28Tobacco History7 (4.7%)Radiation History8 (5.4%)BRCA 1/2 Status10 (6.7%)Family History38 (25.5%)Unilateral vs. Bilateral NSMUnilateral: 76 (51.0%) Bilateral: 73 (49.0%)Indication for MastectomyTherapeutic: 126 (84.6%) Prophylactic: 23 (15.4%)Neoadjuvant Therapy6 (4.0%)Follow-Up (months) (Range)30.72 (57.6-8.28)Tumor Size (cm)1.41Histologic Type (Percent of Therapeutic NSM)IDC: 82 (66.7%) DCIS: 30 (23.8%) ILC: 7 (5.6%) Invasive Other: 6 (4.8%) Mixed Type: 1 (0.8%)Pathologic StageStage 0: 52 (34.9%) Stage I: 54 (36.2%) Stage IIA: 14 (9.4%) Stage IIB: 8 (5.4%) Stage IIIA: 3 (2.0%) Stage IIIC: 1 (0.7%)Receptor StatusER (+): 90 (60.4%) PR (+): 79 (53.0%) Her 2/neu (+): 6 (4.0%) Ki-67 (High): 35 (23.5%)Positive Nodal Status22 (14.8%) NSM Complications per Patient22 (14.8%)Frozen Section: 6 (7 breasts) (4.0%) Permanent Section: 2 (1.3%)Mastectomy Flap Necrosis12 (8.1%)Nipple-Areola Complex NecrosisPartial-Thickness: 2 (1.3%) Full-Thickness: 1 (0.67%)Nipple-Areola Complex Excision (Patient Preference)1 (0.67%)Implant Extrusion4 (2.7%)CellulitisOral Antibiotics: 12 (8.1%) Intravenous Antibiotics: 2 (1.3%)Hematoma4 (2.7%)Seroma3 (2.0%)Wound Dehiscence1 (0.67%)Capsular Contracture2 (1.3%)Thoracodorsal Nerve Spasm1 (0.67%)Microvascular Free Flap Failure1 (0.67%) Conclusions: We examined our institutional outcomes with NSM and found a locoregional recurrence rate of 0.7% with no nipple-areolar complex recurrence. This rate is significantly lower than aggregate published rates for both NSM and SSM. Citation Format: Guth AA, Frey JD, Alperovich M, Kim JC, Axelrod DM, Shapiro RL, Choi M, Karp NS, Schnabel FR. Oncologic outcomes after nipple-sparing mastectomy: A single-institution experience. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-12-08.